These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33904362)

  • 1. Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study.
    Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Matsumura T; Meguro K; Yamada M; Mimura M; Arai H; Treuer T
    Curr Med Res Opin; 2021 Aug; 37(8):1331-1339. PubMed ID: 33904362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study.
    Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Treuer T; Sato M; Kahle-Wrobleski K; Meguro K; Yamada M; Mimura M; Arai H
    J Alzheimers Dis; 2020; 74(1):127-138. PubMed ID: 31985460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
    Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
    J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
    Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
    BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study.
    Olazarán J; Agüera-Ortiz L; Argimón JM; Reed C; Ciudad A; Andrade P; Dilla T
    Int Psychogeriatr; 2017 Dec; 29(12):2081-2093. PubMed ID: 28720158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
    Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
    J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS.
    Reed C; Belger M; Scott Andrews J; Tockhorn-Heidenreich A; Jones RW; Wimo A; Dodel R; Haro JM
    Int Psychogeriatr; 2020 Feb; 32(2):267-277. PubMed ID: 31134870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
    Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
    Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia.
    Belger M; Haro JM; Reed C; Happich M; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
    Eur J Health Econ; 2019 Apr; 20(3):343-355. PubMed ID: 30178148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours.
    Haro JM; Kahle-Wrobleski K; Bruno G; Belger M; Dell'Agnello G; Dodel R; Jones RW; Reed CC; Vellas B; Wimo A; Argimon JM
    J Nutr Health Aging; 2014 Jul; 18(7):677-84. PubMed ID: 25226106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
    Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
    J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer's Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study.
    Chandler JM; Ye W; Mi X; Doty EG; Johnston JA
    J Alzheimers Dis; 2024; 100(2):563-578. PubMed ID: 38875031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes.
    Jones RW; Lebrec J; Kahle-Wrobleski K; Dell'Agnello G; Bruno G; Vellas B; Argimon JM; Dodel R; Haro JM; Wimo A; Reed C
    Dement Geriatr Cogn Dis Extra; 2017; 7(1):87-100. PubMed ID: 28611822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of diabetes on caregiver burden in an observational study of individuals with Alzheimer's disease.
    Lebrec J; Ascher-Svanum H; Chen YF; Reed C; Kahle-Wrobleski K; Hake AM; Raskin J; Naderali E; Schuster D; Heine RJ; Kendall DM
    BMC Geriatr; 2016 May; 16():93. PubMed ID: 27142529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease.
    Reed C; Belger M; Vellas B; Andrews JS; Argimon JM; Bruno G; Dodel R; Jones RW; Wimo A; Haro JM
    Int Psychogeriatr; 2016 Feb; 28(2):247-59. PubMed ID: 26307191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1.
    Robinson RL; Rentz DM; Andrews JS; Zagar A; Kim Y; Bruemmer V; Schwartz RL; Ye W; Fillit HM
    J Alzheimers Dis; 2020; 75(2):437-450. PubMed ID: 32250304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational study.
    Belger M; Haro JM; Reed C; Happich M; Kahle-Wrobleski K; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
    BMC Med Res Methodol; 2016 Jul; 16():83. PubMed ID: 27430559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How useful is the EQ-5D in assessing the impact of caring for people with Alzheimer's disease?
    Reed C; Barrett A; Lebrec J; Dodel R; Jones RW; Vellas B; Wimo A; Argimon JM; Bruno G; Haro JM
    Health Qual Life Outcomes; 2017 Jan; 15(1):16. PubMed ID: 28109287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study.
    Gustavsson A; Jonsson L; Rapp T; Reynish E; Ousset PJ; Andrieu S; Cantet C; Winblad B; Vellas B; Wimo A;
    J Nutr Health Aging; 2010 Oct; 14(8):648-54. PubMed ID: 20922341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of societal costs in Alzheimer's disease: GERAS study baseline results.
    Dodel R; Belger M; Reed C; Wimo A; Jones RW; Happich M; Argimon JM; Bruno G; Vellas B; Haro JM
    Alzheimers Dement; 2015 Aug; 11(8):933-45. PubMed ID: 25846298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.